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Background: Near infrared (NIR) photoimmunotherapy (PIT) is a new type of cancer treatment based on a
monoclonal antibody (mAb)-NIR phthalocyanine dye, (IR700) conjugate. In vitro cancer-specific cell death occurs
during NIR light exposure in cells previously incubated with mAb-IR700 conjugates. However, documenting rapid
cell death in vivo is more difficult.
Methods: A luciferase-transfected breast cancer cell (epidermal growth factor receptor+, MDA-MB-468luc cells) was
produced and used for both in vitro and in vivo experiments for monitoring the cell killing effect of PIT. After
validation of cytotoxicity with NIR exposure up to 8 J/cm2 in vitro, we employed an orthotopic breast cancer model
of bilateral MDA-MB-468luc tumors in female athymic mice, which subsequently received a panitumumab-IR700
conjugate in vivo. One side was used as a control, while the other was treated with NIR light of dose ranging from
50 to 150 J/cm2. Bioluminescence imaging (BLI) was performed before and after PIT.
Results: Dose-dependent cell killing and regrowth was successfully monitored by the BLI signal in vitro. Although
tumor sizes were unchanged, BLI signals decreased by >95% immediately after PIT in vivo when light intensity was
high (>100 J/cm2), however, in mice receiving lower intensity NIR (50 J/cm2), tumors recurred with gradually
increasing BLI signal.
Conclusion: PIT induced massive cell death of targeted tumor cells immediately after exposure of NIR light that
was demonstrated with BLI in vivo.
Keywords: Photoimmunotherapy, Theranostics, Cell death, Epidermal growth factor receptor, Molecular targeting,
Monoclonal antibody, Bioluminescence imagingBackground
Conventional cancer therapies cause damage or tox-
icity in normal tissues, thus requiring dose reductions,
which, in turn, limit the effectiveness of such agents
[1,2]. In general, treatments that maximize target-cell
killing while minimizing damage to normal cells are
highly desirable. Targeted molecular cancer therapies
offer the promise of more effective tumor targeting
with fewer side effects than conventional cancer ther-
apies, however, only limited success has thus far, been
achieved. Combining drugs with activating physical en-
ergy, such as light or heat, is a potential method of* Correspondence: kobayash@mail.nih.gov
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distribution, and reproduction in any mediumimproving therapeutic selectivity. We recently reported
a new type of highly selective cancer therapy, termed
“photoimmunotherapy” or PIT, which utilizes a monoclo-
nal antibody (mAb)-bound to the photosensitizing phtha-
locyanine dye, IRDye700DX (IR700) to target cancer cells
and an exposure of near infrared (NIR) light to specifically
kill those cells. Remarkably, the mAb-IR700 conjugate is
only active as a therapeutic agent, when it is bound to the
target cell membrane; otherwise it had no effect on adja-
cent non-expressing cells [3]. Following NIR light expos-
ure, immediate, target-selective necrotic cell death was
observed in vitro using cytotoxicity assays, however,
in vivo assessment of rapid cell death before decreasing
tumor size is more challenging. Although progressive
tumor shrinkage in vivo was observed 3-4 days after PIT,
even after only a single administration of mAb-IR700 andtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tainty over how quickly cell death occurs [4]. Such infor-
mation could be useful in optimizing PIT dosing and light
exposure.
Bioluminescence (BLI) is a well established method of
determining in vivo viability [5,6], since the BLI reaction
requires both oxygen and ATP to actively transport the
substrate luciferin and subsequently catalyze the photo-
chemical reaction [7]. In this study we used BLI to
monitor the kinetics of tumor cell death after PIT in epi-
dermal growth factor receptor (EGFR) expressing ortho-
topic breast tumors after the mouse received anti-EGFR
panitumumab-IR700 conjugate (Pan-IR700) followed by
varying intensities of NIR light. Results were compared
to identical tumors that were not exposed to NIR in the
same mice. This method allows for the detection of
massive cellular death in vivo immediately after PIT.Methods
Reagents
A water soluble, silicon-phthalocyanine derivative, IRDye
700DX NHS ester (IR700; C74H96N12Na4O27S6Si3, mo-
lecular weight of 1954.22) was obtained from LI-COR
Bioscience (Lincoln, NE). Panitumumab, a fully huma-
nized IgG2 mAb directed against the human EGFR, was
purchased from Amgen (Thousand Oaks, CA). All other
chemicals were of reagent grade.Synthesis of IR700-conjugated panitumumab
Panitumumab (1 mg, 6.8 nmol) was incubated with
IR700 (66.8 μg, 34.2 nmol, 5 mmol/L in DMSO) in 0.1
mol/L Na2HPO4 (pH 8.5) at room temperature for 2 h.
The mixture was purified with a Sephadex G50 column
(PD-10; GE Healthcare, Piscataway, NJ). The protein
concentration was determined with Coomassie Plus pro-
tein assay kit (Thermo Fisher Scientific Inc, Rockford, IL)
by measuring the absorption at 595 nm with spectroscopy
(8453 Value System; Agilent Technologies, Santa Clara,
CA). The concentration of IR700 was measured by ab-
sorption with spectroscopy to confirm the number of
fluorophore molecules conjugated to each mAb molecule.
The number of IR700 per antibody was ~3.Cells
EGFR-expressing MDA-MB-468luc, stable luciferase-
transfected cells [8] were grown in RPMI 1640 supple-
mented with 10% fetal bovine serum and 1% penicillin/
streptomycin in tissue culture flasks in a humidified in-
cubator at 37°C in an atmosphere of 95% air and 5% car-
bon dioxide. Balb/3T3 cells (ATCC, Rockville, MD) were
used as a control in the same culture condition.Fluorescence microscopy
To detect the antigen specific localization of IR700,
fluorescence microscopy was performed (BX51 or IX81;
Olympus America, Melville, NY). MDA-MB-468luc or
1:1 mixture of MDA-MB-468luc and Balb/3T3 cells
were seeded on a cover glass-bottomed dishes and incu-
bated 24 h. Pan-IR700 was added to the culture medium
at 10 μg/mL and incubated for 6 h at 37°C, then cells
were washed with PBS. The filter was set to detect
IR700 fluorescence with a 590–650 nm excitation filter,
and a 665–740 nm band pass emission filter.
In vitro PIT
Cells were seeded into 96 well plate or 35 mm cell cul-
ture dishes and incubated 8 h. Medium was replaced
with fresh culture medium containing 10 μg/ml of Pan-
IR700 and incubated over night at 37°C. After washing
with PBS, phenol red free culture medium was added.
Then, cells were irradiated with a red light-emitting
diode (LED), which emits light at 670 to 710 nm wave-
length (L690-66-60; Marubeni America Co., Santa Clara,
CA), and a power density of 25 mW/cm2 as measured with
optical power meter (PM 100, Thorlabs, Newton, NJ).
Phototoxicity assay
Cytotoxic effects of PIT with Pan-IR700 were deter-
mined with luciferase activity assay and flowcytometric
LIVE⁄DEAD® Fixable Green Dead Cell Stain Kit (Invitrogen,
Carlsbad, CA), which can detect compromised cell mem-
branes. For luciferase activity assay, D-luciferin (Gold
Biotechnology, St. Louis, MO) was added to culture
media at 150 μg/ml and analyzed on a biolumines-
cence imaging system (Photon Imager; Biospace Lab,
Paris, France). For the flowcytometric assay, cells were
trypsinized after treatment and washed with PBS.
Green fluorescent reactive dye was added in the cell
suspension and incubated at room temperature for 30
min, followed by analysis on a flow cytometer (FACS
Calibur, BD Biosciences, San Jose, CA).
Orthotopic breast tumor model
All in vivo procedures were conducted in compliance
with the Guide for the Care and Use of Laboratory Ani-
mal Resources (1996), US National Research Council,
and approved by the National Cancer Institute Animal
Care and Use Committee. Six- to eight-week-old female
homozygote athymic nude mice were purchased from
Charles River (NCI-Frederick, Frederick, MD). During
the procedure, mice were anesthetized with isoflurane.
Two million MDA-MB-468luc cells were implanted into
the mammary fat pads bilaterally. D-luciferin (15 mg/ml,
200 μl) was injected intraperitoneally into mice 6 days
after cell implantation, and analyzed with Photon Imager
for luciferase activity. Mice were selected for further
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size and BLI signal.
In vivo PIT with Pan-IR700
As there was no treatment effect for MDA-MB-468luc
tumors after the single administration of unconjugated
panitumumab, selected mice were randomized into 5
groups of 5 animals per group for the following treat-
ments: (1) no treatment; (2) 100 μg of Pan-IR700 i.v., no
NIR light exposure; (3) 100 μg of Pan-IR700 i.v., NIR
light was administered at 50 J/cm2 on day 1 after injec-
tion; (4) 100 μg of Pan-IR700 i.v., NIR light was adminis-
tered at 100 J/cm2 on day 1 after injection; (5) 100 μg of
Pan-IR700 i.v., NIR light was administered at 150 J/cm2
on day 1 after injection. NIR light exposure was per-
formed 8 days after cell implantation. Mice images were
acquired over time with a fluorescence imager (Pearl
Imager; LI-COR Biosciences) for detecting IR700 fluor-
escence, and Photon Imager for BLI. For analyzingFigure 1 EGFR-specific PIT in vitro. (A) MDA-MB-468luc cells were treate
IR700). Necrotic cell death was observed upon excitation with NIR light (Af
cells were co-cultured and treated with Pan-IR700 (Before and after Pan-IR7
irradiation results in dose dependent cell death as determined by the cyto
test).fluorescence and BLI, regions of interest (ROI) of similar
size were placed over the entire tumor. The average
fluorescence intensity of each ROI was measured. When
comparing fluorescence target-to-background ratios
(TBR), ROIs were placed in the surrounding non-tumor
region.
Histological analysis
To evaluate serial histological changes immediately after
PIT with various NIR light doses, microscopic study was
performed (BX51, Olympus America). MDA-MB-468luc
tumors were harvested in 10% formalin immediately
after 50, 100, and 150 J/cm2 of NIR light exposure. Serial
10-μm slice sections were fixed on 2 glass slides with
Hematoxylin and Eosin (H-E) staining.
Statistical analysis
Data are expressed as means ± s.e.m. from a minimum
of three experiments. Statistical analyses were carriedd with Pan-IR700 and observed with microscopy (Before and after Pan-
ter). (B) Both EGFR positive (MDA-MB-468luc) and negative (Balb/3T3)
00). EGFR-specific necrotic cell death was observed (After). (C) NIR light
toxicity assay. (n = 3, *** P<0.001 vs. non treatment control, Student’s t
Figure 2 Effect of phototoxicity in response to Pan-IR700
mediated PIT. Cell viability was analyzed with (A) bioluminescence
and (B) fluorescence LIVE/DEAD cytotoxicity assay after NIR light
irradiation in MDA-MB-468luc cells.
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Pad Software, La Jolla, CA). Student’s t test was used to
compare the treatment effects with that of controls.
Results
Target-specific, dose-dependent NIR light-induced
necrotic cell death in response to Pan-IR700 mediated PIT
Fluorescence microscopy was performed to confirm target-
specific localization of Pan-IR700. IR700 was mainly loca-
lized to the cell membrane and lysosomes of EGFR positive
MDA-MB-468luc cells. When these cells were observed
during continuous NIR light exposure, almost immediate
swelling, budding and rupture of the lysosome was
observed leading to irreversible cell death (Figure 1A).
MDA-MB-468luc and EGFR negative Balb/3T3 cells were
co-incubated to confirm cell-specific killing. Pan-IR700 did
not localize to Balb/3T3 cells which were not killed by ex-
posure to NIR (Figure 1B). To confirm that rapid photo-
toxic cell death had occurred, we used the LIVE/DEAD
assay, which can detect early cell membrane damage. Cell
death increased significantly in a dose dependent manner
with the intensity of NIR light (P<0.001) but no cell death
was observed in the absence of Pan-IR700 incubation or in
the absence of light (Figure 1C).
Bioluminescence imaging of rapid tumor killing in
response to Pan-IR700 mediated PIT
We next examined the effect of rapid Pan-IR700-
mediated phototoxicity using BLI in vitro. Viable MDA-
MB-468luc cells ranging from 3.1 × 104 to 1.0 × 106 were
detected with BLI prior to NIR exposure (Additional file
1 Figure S1). Low levels of NIR light irradiation dose
(~2.0 J/cm2) resulted in initially decreased BLI followed
by recovery of signal as the cells regrew. In contrast,
higher levels of NIR light exposure (8.0 J/cm2) resulted
in permanent loss of BLI signal. Interestingly, BLI activ-
ity did not immediately disappear after NIR light irradi-
ation even with high levels of exposure (Figure 2A)
probably because the budding cells released all the ne-
cessary components of the BLI photochemical reaction
(luciferase, ATP, oxygen, and luciferin) into the sur-
rounding well permitting the reaction to persist even
while the cells were evidently dead based on the cytotox-
icity assay, which showed prompt increases in the num-
ber of dead cells. Exposure to higher doses of NIR led to
the death of more than 90% of the cells and BLI signal
remained reduced over time (Figure 2B).
In vivo monitoring of the acute therapeutic effects of Pan-
IR700 mediated PIT
Orthotopically implanted MDA-MB-468luc breast cancer
cells were injected into mammary fat pads bilaterally.
Tumors were first recognized at approximately 4 mm in
diameter and 6 days after cell injection. BLI was performedat 6 days to select 25 mice (5 groups of 5 mice per group)
with symmetrical levels of bioluminescence. In addition to
symmetry on BLI we also selected for tumors of similar size
and those that demonstrated similar IR700 fluorescence at
day 7 post cell injection. Mice received Pan-IR700 at day 6
and typically the right sided tumors were exposed to NIR
light irradiation at day 7, while the left sided tumors were
covered. BLI was obtained at 4 h intervals since this is how
long it took for the BLI signal to extinguish after luciferin
administration. BLI showed a significant decrease in signal
compared to baseline within 4 h after NIR light exposure,
compared with the various control groups: Pan-IR700+
NIR- and Pan-IR700-, NIR + and Pan-IR700-, NIR-. BLI
revealed that irradiating with 50 J/cm2 resulted in the re-
covery of BLI signal over time, whereas tumors irradiated
with 150 J/cm2 did not show recovery (Figure 3A, B). In
order to demonstrate immediate cell killing, we randomized
15 mice in 3 groups 24 h before NIR irradiation, and irra-
diated each tumor with 100 J/cm2, followed by BLI at 0, 1
and 4 h after irradiation. As shown in Figure 3C, BLI signal
decreased immediately after NIR light irradiation probably
because ATP is hydrolyzed during PIT preventing bio-
luminescence reactions. Since IR700 is also a fluorescent
dye, we were also able to observe PIT effects with a
fluorescence camera. IR700 fluorescence was detected in
MDA-MB-468luc tumors before NIR light irradiation with
a high target-to-background ratio (TBR = ~ 8), but
was markedly decreased to nearly background level
(TBR = ~1) immediately after NIR light irradiation. In
contrast, IR700 fluorescence intensity in non-treated
Figure 3 In vivo fluorescence and bioluminescence imaging of orthotopic breast tumors in response to Pan-IR700 mediated PIT.
(A) Monitoring bioluminescence activity in response to Pan-IR700 mediated PIT (n = 5 each). B: just before NIR light treatment. Bioluminescence
signals of tumors in 100 and 150 J/cm2 treated groups showed significant difference with that in control or 50 J/cm2 treated group at all time
points examined after PIT (P<0.001). (B) Monitoring bioluminescence activity ratio of treated tumor to internal control (n = 5 each). B: just before
NIR light treatment. Bioluminescence signals of tumors in 100 and 150 J/cm2 treated groups showed significant difference with that in control or
50 J/cm2 treated group at all time points examined after PIT (P<0.001). (C) Rapid changes of bioluminescence activity in response to Pan-IR700
mediated PIT (n = 5 each). Before: 1 d before NIR light treatment. (D) IR700 fluorescence and bioluminescence imaging in response to Pan-IR700
mediated PIT. Representative images are shown. Before: just before NIR light treatment, FLI: IR700 fluorescence imaging, WLI: white light imaging,
BLI: bioluminescence imaging.
Mitsunaga et al. BMC Cancer 2012, 12:345 Page 5 of 8
http://www.biomedcentral.com/1471-2407/12/345(Pan-IR700+, NIR-) control tumors decreased slowly
with time commensurate with the conjugate’s pharmaco-
kinetics (Figure 3D).
Histological analysis
Microscopic evaluation of treated tumors revealed diffuse
necrosis and microhemorrhage with scattered clusters of
damaged tumor cells after PIT with 50-150 J/cm2. Necrotic
damage was more intense and fewer tumor cells remained,when higher energy (150 J/cm2) NIR light was administered
(Figure 4).
Discussion
This study demonstrates that target-selective accumula-
tion of Pan-IR700 in MDA-MB-468luc tumors resulted
in rapid cell death, which was dose dependent based on
the NIR light intensity in the range of 50-150 J/cm2. Im-
mediate cell death after exposure to NIR light could be
Figure 4 Histological findings immediately after PIT with various NIR exposures. Histological specimens of MDA-MB-468luc tumors, which
were treated with PIT at 0, 50, 100, and 150 J/cm2, are shown. All specimens are stained with Hematoxylin and Eosin. A few scattered clusters of
damaged tumor cells are seen within a background of diffuse cellular necrosis and micro-hemorrhage immediately after PIT with 50 J/cm2.
Necrotic damage was more intense when higher intensity NIR light was administered. Scale indicates 50μm.
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less than 3% just after PIT treatment with 100 J/cm2 of
NIR light irradiation, indicating near instantaneous
tumor cell killing in vivo. Fluorescence signal also
decreased immediately after NIR exposure of PIT as
shown in Figure 3D. However, this immediate decrease
of IR700 fluorescence could be induced partly by photo-
bleaching of IR700. This immediate cell death suggests
that the mechanism of PIT-induced tumor cell death is
necrosis via direct physical injury such as pressure waves
induced by local heat elevation and not through slower
death pathways such as apoptosis or autophagy. Lower
doses of light resulted in incomplete cell killing causing
tumor regrowth as demonstrated by increasing BLI sig-
nal. Higher doses of light (e.g. 150 J/cm2) resulted in
complete responses. Thus, BLI are able to monitor
therapeutic responses to PIT.
Paradoxically, the BLI results appeared to be less rapid
when cells were tested in vitro. Although Pan-IR700 trea-
ted MDA-MB-468luc cells were rapidly and selectively
killed in response to NIR light irradiation, BLI appeared to
show that cell killing was slower than in vivo cell killing
[3]. Nearly instantaneous cell killing was demonstrated
with the LIVE/DEAD cytotoxicity assay, which detected
early cellular membrane damage after low levels (less than
2 J/cm2 ) of NIR light while BLI signal was reduced only
after 4 h post NIR exposure [9,10]. These data suggest that
disrupted cellular membranes, which can be defined as“dead” by LIVE/DEAD staining assay may undergo rapid
cell surface repair to reseal cellular membrane, while, ag-
gressively disrupted cells after strong NIR irradiation
(more than 2 J/cm2) were irreversibly damaged and could
not repair the disrupted membrane [11]. However, an add-
itional factor is that BLI signal was artifactually preserved
in vitro. Even after severe mechanical disruption of a cell
membrane all the necessary elements for BLI including
ATP, oxygen and luciferin still exist within the well in suf-
ficient concentrations to produce a photochemical reac-
tion. In contrast, when PIT is performed in vivo, released
ATP is rapidly hydrolyzed in the local microenvironment
resulting in rapid loss of BLI signal. Thus, BLI may be a
more valuable tool for in vivo monitoring than for in vitro
monitoring of cell therapies, which are based on rapid
physical damage, as opposed to chemical or biological
damage to cancer cells.
Fluorescent proteins (FPs) are a potential alternative
for monitoring tumor growth in vivo [12-15]. Fluores-
cence imaging using FPs are better direct and stable
method for longitudinal monitoring therapeutic effects
of photo-therapy [16,17] for days or weeks than the bio-
luminescence imaging, which is used in this study, be-
cause most of FPs are stable in solution for days in vitro
[18] and fluoresced before FPs are taken up and catabo-
lized by macrophages in vivo [12]. Therefore, fluores-
cence imaging has already been used for longitudinal
monitoring of therapeutic effects of PIT [4]. However,
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happens in cancer therapy, did not depict after with the
fluorescence imaging for hours but depicted with the
bioluminescence imaging because fluorescent substances
are stable than ATP, which hydrized immediately in vivo.
Therefore, the bioluminescence imaging is theoretically
and practically the appropriate method for detecting this
unique PIT-induced immediate massive cell death.
Proper controls are vital to prove that the cell killing is
related to the combination of Pan-IR700 and NIR light
exposure. We achieved this by implanting breast tumors
bilaterally in the fat pads of mice and selecting for mice
with tumors that were symmetric in size and BLI/fluor-
escence signals just before PIT. Controls included
tumors that did not receive Pan-IR700 but did receive
light, tumors that received Pan-IR700 but did not re-
ceive NIR light and those that received neither agent nor
light. No cell killing was observed in these controls. In
contrast to a previous study of PIT, which employed a
subcutaneous xenograft, we employed an orthotopic bi-
lateral breast cancer tumor model and used one tumor
as an internal control [19]. Such symmetry is more easily
achieved in orthotopic vs. subcutaneous models and this
model was also able to demonstrate that response was
dose dependent with regard to light exposure.
Conclusions
Immediate cytotoxicity induced by PIT was demon-
strated using bioluminescence imaging in vivo. The im-
mediate cell killing demonstrated by BLI strongly
suggests that the mechanism of action of PIT is necrosis
due to rapid mechanical membrane disruption caused by
local heating and induced pressure waves. This is sup-
ported by direct observational microscopic evidence that
rapid cell swelling and budding is seen in cells previously
treated with a mAb-IR700 conjugate and subsequently
exposed to NIR light. This data support the concept that
PIT could be highly controlled by appropriate dosing of
light to specific tumor cells identified by their IR700
fluorescence, resulting in a true “see and treat” paradigm
that could be useful during surgical or endoscopic pro-
cedures. Practically, surgeons or endoscopy physicians
could “see” tumors with the fluorescence of IR700, and
then “treat” them by surgery combined with exposing
the NIR light to achieve complete treatment of a patient.
This result suggests that physicians should not misread
remaining persistent fluorescence signal as a sign of sur-
vived tumors.
Additional file
Additional file 1: Figure S1. Sensitivity of bioluminescence assay in
serially diluted viable MDA-MB-468luc cells. BLI signal could be detected
in as few as 3.1x104 cells MDA-MB-468luc.Abbreviations
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